Collectively, these findings highlight tiliacorinine’s strong binding affinities to pivotal cholangiocarcinoma-related targets, including MTOR, SRC, MMP9, and MAPK1, underscoring its potential as a promising multi-target therapeutic candidate. Here, MAPK1 is linked to cholangiocarcinoma.